Dry Eye Disease (DED) Market Expected to Witness Significant Growth Through 2036, Driven by Rising Disease Burden, Expanding Treatment Options, and Emerging Novel Therapies | DelveInsight

The Dry Eye Disease (DED) market is expected to witness significant growth across the Seven Major Markets (7MM) during the forecast period (2022-2036). Market growth is anticipated to be driven by the increasing prevalence of dry eye disease, rising awareness and diagnosis rates, an aging population, excessive digital device usage, environmental and lifestyle risk factors, and the anticipated launch of innovative therapies with novel mechanisms of action. Continuous advancements in prescription medications and emerging pipeline products are expected to transform the DED treatment landscape over the coming years.

DelveInsight's "Dry Eye Disease (DED) Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive assessment of disease epidemiology, current treatment practices, marketed and emerging therapies, market trends, pricing analysis, therapy uptake, reimbursement landscape, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report further evaluates patient burden, competitive intelligence, key opinion leader perspectives, and commercial opportunities expected to shape the DED market through 2036.

The report also delivers detailed insights into historical and forecasted market performance, epidemiological trends, patient journey, treatment algorithms, unmet needs, SWOT analysis, pricing dynamics, and the evolving competitive landscape to support strategic decision-making for stakeholders operating in the ophthalmology market.

To know more about the Dry Eye Disease (DED) market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Dry Eye Disease (DED) Market Report

• The Dry Eye Disease (DED) market is expected to grow significantly across the 7MM during the forecast period (2022-2036), supported by increasing diagnosed patient populations, growing adoption of prescription therapies, and anticipated launches of emerging disease-modifying treatments.
• According to DelveInsight estimates, the 7MM accounted for approximately 55 million diagnosed prevalent cases of Dry Eye Disease in 2025, with patient numbers expected to increase steadily through 2036.
• The United States accounted for more than 22 million diagnosed prevalent cases in 2025, representing the largest patient pool among the Seven Major Markets.
• Women accounted for nearly 34 million diagnosed prevalent cases, while men represented approximately 20 million cases across the 7MM in 2025, highlighting the higher disease burden among females.
• The 50 years and above age group accounted for more than 40 million diagnosed prevalent cases in 2025, emphasizing the strong association between aging and Dry Eye Disease.
• Currently marketed therapies include RESTASIS, TYRVAYA, XIIDRA, EYSUVIS, CEQUA, IKERVIS, DIQUAS LX, MIEBO, VEVYE, and the recently approved TRYPTYR (acoltremon ophthalmic solution), while emerging therapies such as PL9643, Reproxalap, and ST-100 (vezocolmitide) are expected to further strengthen the treatment landscape.

Key Factors Driving the Dry Eye Disease (DED) Market

Rising Disease Burden and Aging Population
Increasing prevalence of Dry Eye Disease, particularly among older adults and women, together with population aging, continues to expand the diagnosed patient pool and drive demand for effective long-term treatment options.

Growing Digital Device Usage and Environmental Risk Factors
Excessive screen time, environmental pollutants, smoke exposure, aging, and lifestyle-related factors are contributing to rising incidence of Dry Eye Disease, supporting continued market expansion.

Expanding Therapeutic Landscape
The availability of recently approved therapies such as TRYPTYR, MIEBO, and VEVYE, along with promising late-stage pipeline candidates including PL9643, Reproxalap, and ST-100, is expected to significantly improve treatment outcomes and market growth.

Improved Diagnosis and Disease Awareness
Growing awareness among patients and healthcare professionals, combined with improved diagnostic techniques including Schirmer's test, tear breakup time assessment, tear osmolarity testing, and ocular surface evaluation, is enabling earlier diagnosis and treatment initiation.

Dry Eye Disease (DED) Market Analysis

Dry Eye Disease is one of the most common chronic ocular surface disorders, characterized by inadequate tear production or excessive tear evaporation, leading to ocular discomfort, inflammation, and visual disturbances. Current management includes artificial tears, anti-inflammatory prescription therapies, punctal plugs, meibomian gland therapy, eyelid hygiene, lifestyle modifications, and advanced procedural interventions. According to DelveInsight, increasing disease awareness, rising diagnosis rates, continuous introduction of innovative therapies, and a robust late-stage pipeline are expected to support sustained growth of the Dry Eye Disease market across the Seven Major Markets through 2036.

Get a Free sample for the Dry Eye Disease (DED) Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Dry Eye Disease (DED) Competitive Landscape

The Dry Eye Disease (DED) treatment landscape has evolved considerably over the past few years with the approval of several novel therapies targeting ocular surface inflammation, tear film instability, and meibomian gland dysfunction. Current management involves a multimodal approach that includes artificial tears, lubricating eye drops, topical anti-inflammatory agents, immunomodulators, punctal plugs, meibomian gland therapies, dietary supplements, and lifestyle modifications. Recently approved therapies such as TRYPTYR, VEVYE, MIEBO, TYRVAYA, CEQUA, and EYSUVIS have expanded treatment options, while multiple late-stage pipeline therapies are expected to further strengthen the market through 2036.

Leading companies developing therapies for Dry Eye Disease include Alcon, Bausch + Lomb, Harrow Eye, Sun Pharmaceutical, Viatris, Palatin Technologies, Aldeyra Therapeutics, Stuart Therapeutics, and others.

TRYPTYR (acoltremon ophthalmic solution 0.003%): Alcon
TRYPTYR (acoltremon ophthalmic solution 0.003%) is a TRPM8 receptor agonist developed by Alcon for the treatment of Dry Eye Disease. The therapy stimulates corneal sensory nerves to enhance natural tear production and improve ocular surface hydration. In May 2025, the US FDA approved TRYPTYR for the treatment of Dry Eye Disease, making it one of the newest additions to the therapeutic landscape. In July 2025, Alcon commercially launched TRYPTYR in the United States, expanding treatment options for millions of patients living with DED.

MIEBO (perfluorohexyloctane ophthalmic solution): Bausch + Lomb / Novaliq
MIEBO is a water-free, preservative-free ophthalmic solution approved for Dry Eye Disease associated with Meibomian Gland Dysfunction (MGD). Developed by Novaliq and commercialized by Bausch + Lomb, the therapy stabilizes the tear film lipid layer, reduces tear evaporation, and improves both signs and symptoms of evaporative dry eye disease. The therapy received US FDA approval in 2023 and has become an important treatment option for patients with evaporative DED.

VEVYE (cyclosporine ophthalmic solution): Harrow Eye / Novaliq
VEVYE is a water-free cyclosporine ophthalmic solution developed by Novaliq and commercialized by Harrow Eye. Approved by the US FDA in June 2023, the therapy utilizes a novel water-free formulation that improves cyclosporine delivery without oils or surfactants. VEVYE is administered twice daily and provides rapid relief while addressing both the signs and symptoms of Dry Eye Disease.

PL9643: Palatin Technologies
PL9643 is a synthetic melanocortin receptor pan-agonist designed to reduce ocular inflammation through modulation of the melanocortin receptor pathway. The therapy represents a novel mechanism of action compared with currently marketed DED treatments. In November 2025, Palatin Technologies reported positive Phase III MELODY-1 results, demonstrating statistically significant complete symptom resolution across multiple endpoints. In February 2026, the company announced the sublicensing of PL9643 for Dry Eye Disease following an agreement executed in January 2026.

Reproxalap: Aldeyra Therapeutics
Reproxalap is a first-in-class reactive aldehyde species (RASP) modulator being developed by Aldeyra Therapeutics for Dry Eye Disease. The therapy targets inflammatory pathways involved in ocular surface disease. In March 2026, the US FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA), citing insufficient efficacy despite no major safety or manufacturing concerns. The company plans further discussions with the FDA regarding the regulatory pathway.

ST-100 (vezocolmitide): Stuart Therapeutics
ST-100 (vezocolmitide) is a collagen mimetic peptide developed by Stuart Therapeutics to restore damaged collagen within the ocular surface and improve tissue homeostasis. The therapy demonstrated encouraging clinical activity, and in June 2025, Stuart Therapeutics reported initial Phase III clinical results in patients with Dry Eye Disease.

Discover more about therapies expected to transform the Dry Eye Disease (DED) market @ Dry Eye Disease (DED) Treatment Landscape

Recent Developments in the Dry Eye Disease (DED) Market

• In July 2025, Alcon announced the commercial launch of TRYPTYR (acoltremon ophthalmic solution 0.003%) in the United States following its FDA approval.
• In May 2025, the US FDA approved TRYPTYR for the treatment of Dry Eye Disease, introducing a novel TRPM8 receptor agonist to the market.
• In February 2026, Palatin Technologies announced the sublicensing of PL9643 following execution of a licensing agreement and receipt of upfront milestone payments.
• In November 2025, Palatin Technologies reported positive Phase III MELODY-1 data for PL9643, demonstrating statistically significant improvements across multiple Dry Eye Disease symptom endpoints.
• In March 2026, Aldeyra Therapeutics received a US FDA Complete Response Letter (CRL) for the New Drug Application of Reproxalap, with no significant safety concerns identified.
• In June 2025, Stuart Therapeutics announced initial Phase III clinical results evaluating ST-100 (vezocolmitide) in Dry Eye Disease.

What is Dry Eye Disease (DED)?

Dry Eye Disease (DED), also known as Dry Eye Syndrome (DES), is a chronic multifactorial disorder characterized by inadequate tear production or excessive tear evaporation, resulting in ocular surface inflammation, discomfort, visual disturbances, and tear film instability. Common symptoms include dryness, burning sensation, foreign body sensation, excessive tearing, redness, blurred vision, light sensitivity, and eye fatigue. Risk factors include aging, prolonged digital device use, meibomian gland dysfunction, autoimmune disorders, hormonal changes, environmental exposure, and certain medications. Diagnosis typically involves Schirmer's test, tear breakup time (TBUT), slit-lamp examination, ocular surface staining, tear osmolarity assessment, and meibomian gland evaluation.

Dry Eye Disease (DED) Epidemiology Segmentation

The DelveInsight report assesses the epidemiology of Dry Eye Disease across the Seven Major Markets (7MM) during 2022-2036, segmented into:
• Total Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM
• Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases
• Country-specific epidemiology across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Download the report to understand the key epidemiology trends, emerging therapies, competitive landscape, and future market opportunities in Dry Eye Disease (DED):

https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Dry Eye Disease (DED) Market Report

• Study Period: 2022-2036
• Coverage: Seven Major Markets (United States, EU4 [Germany, France, Italy, Spain], the United Kingdom, and Japan)
• Key Companies: Alcon, Bausch + Lomb, Novaliq, Harrow Eye, Sun Pharmaceutical, Viatris, Palatin Technologies, Aldeyra Therapeutics, Stuart Therapeutics, and others
• Marketed Therapies: TRYPTYR, RESTASIS, XIIDRA, TYRVAYA, CEQUA, EYSUVIS, MIEBO, VEVYE, IKERVIS, DIQUAS LX, and others
• Emerging Therapies: PL9643, Reproxalap, ST-100 (vezocolmitide), and other pipeline candidates
• Epidemiology Segmentation: Diagnosed prevalence by gender, age group, disease severity, and country
• Market Dynamics: Historical and forecasted market size, therapy uptake, pricing analysis, analogue assessment, reimbursement scenario, SWOT analysis, unmet needs, KOL views, and competitive intelligence.

Table of Contents

• Dry Eye Disease (DED) Market Report Introduction
• Dry Eye Disease (DED) Market Executive Summary
• Dry Eye Disease (DED) Market Overview at a Glance
• Dry Eye Disease (DED) Disease Background and Overview
• Dry Eye Disease (DED) Classification
• Dry Eye Disease (DED) Signs and Symptoms
• Dry Eye Disease (DED) Etiology and Risk Factors
• Dry Eye Disease (DED) Diagnosis
• Dry Eye Disease (DED) Treatment and Management
• Dry Eye Disease (DED) Treatment Guidelines
• Dry Eye Disease (DED) Epidemiology and Market Methodology
• Dry Eye Disease (DED) Epidemiology Analysis
• Dry Eye Disease (DED) Patient Population Analysis
• Dry Eye Disease (DED) Current Treatment Landscape
• Dry Eye Disease (DED) Marketed Therapies
• Dry Eye Disease (DED) Emerging Therapies
• Dry Eye Disease (DED) Emerging Therapy Assessment
• Dry Eye Disease (DED) Market Size Analysis (2022-2036)
• Dry Eye Disease (DED) Market Size by Therapies
• Dry Eye Disease (DED) Drug Uptake Analysis
• Dry Eye Disease (DED) Pricing Trends and Analogue Assessment
• Dry Eye Disease (DED) Competitive Landscape
• Dry Eye Disease (DED) Key Companies
• Dry Eye Disease (DED) Key Therapies
• Dry Eye Disease (DED) Conjoint Analysis
• Dry Eye Disease (DED) Key Market Forecast Assumptions
• Dry Eye Disease (DED) Unmet Needs
• Dry Eye Disease (DED) SWOT Analysis
• Dry Eye Disease (DED) Key Opinion Leader (KOL) Views
• Dry Eye Disease (DED) Market Access and Reimbursement
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.